-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★ 2021 Oncolytic Virus Drug Development ForumHeyuan Bio will meet you in no time.
September 9, 2009/eMedClub News/--Recently, Candel Therapeutics, a late-stage clinical biopharmaceutical company, announced that its new oncolytic virus immunotherapy CAN-2409 has completed a key phase 3 study in patients with high-risk local prostate cancer Recruitment of patients
.
This clinical trial aims to evaluate the therapeutic effect of CAN-2409 in combination with valacyclovir and standard-of-care radiotherapy alone in the treatment of patients with newly diagnosed localized prostate cancer with intermediate and high risk of recurrence
.
Localized prostate cancer is an androgen-dependent tumor.
Androgens can stimulate the growth of prostate cancer cells and disease progression
.
Therefore, endocrine therapy is one of the conventional treatments.
However, as the disease progresses, androgen receptor (AR) mutations, causing endocrine patients to enter a treatment-resistant state
.
However, the side effects of daily surgery and radiotherapy are obvious, and local prostate cancer patients urgently need innovative therapies that can improve their lives
.
CAN-2409 is a replication-deficient engineered virus based on adenovirus, which contains a prodrug-converting enzyme gene encoding herpes simplex virus thymidine kinase (HSV-tk)
.
HSV-tk can convert the small molecule prodrug valacyclovir (FDA approved anti-herpes drug) into toxic metabolites that kill nearby cancer cells
.
CAN-2409 is administered by intratumoral injection, and adenovirus is used as a vector to transport the kinase gene into tumor cells
.
This local intra-tumor administration method minimizes the systemic toxicity associated with systemic intravenous administration and eliminates the need for complex immune evasion or tumor-specific targeting mechanisms.
At the same time, CAN-2409 is also focused on local induction The immune response of the tumor leads to the death of immunogenic cells and the release of tumor-specific antigens in the microenvironment
.
In addition, the adenovirus vector itself sends a strong pro-inflammatory signal to the tumor microenvironment to induce an immune response mediated by specific CD8+ cytotoxic T cells against the injected tumor
.
This dual mechanism enables CAN-2409 to have a powerful and long-lasting attack on many tumor-associated antigens of patients, thereby minimizing antigen escape and tolerance
.
▲The pharmacological effects of CAN-2409 combined with valacyclovir (picture source: Candel's official website) "The combination of CAN-2409 and radiotherapy has been proven to create an immune-stimulating environment that activates the body's immune system to identify and destroy cancer cells," Dr.
Paul Peter Tak, President and CEO of Candel Therapeutics, said, “Patients with localized non-metastatic prostate cancer are in great need of new therapies to improve disease progression, while reducing long-term androgen deprivation therapy and its related side effects
.
We believe that CAN-2409 can improve the prostate.
The prognosis of cancer patients
.
” ▲ Dr.
Paul Peter Tak, President and CEO of Candel Therapeutics (picture source: Candel’s official website) For more details, scan the QR code for a complete reading.
Due to the versatility of adenovirus vectors, CAN -2409 may also have the potential to treat a variety of solid tumors
.
In several ongoing preclinical and clinical settings, CAN-2409 has shown encouraging activity as a monotherapy and in combination with standard-of-care radiotherapy, surgery, chemotherapy, and immune checkpoint inhibitor therapy
.
In addition, to date, more than 700 patients have received good safety dosing, supporting the potential for combination with other treatment strategies without excessive worrying about overlapping adverse events
.
Candel will continue to evaluate the clinical trial effects of CAN-2409 in the treatment of high-grade glioma, non-small cell lung cancer, pancreatic cancer and prostate cancer
.
Candel is a biopharmaceutical company focused on helping patients fight cancer through oncolytic virus immunotherapy.
At present, the company has established an oncolytic virus immunotherapy platform based on new genetically modified adenovirus and herpes simplex virus (HSV) constructs
.
CAN-2409 is the main product candidate for the adenovirus platform, and CAN-3110 is the main product candidate for the HSV platform
.
▲Candel Therapeutics product pipeline (picture source: Candel official website) Reference materials: 1.
https:// -can-2409-in-combination-with-valacyclovir-for-the-treatment-of-intermediate-high-risk-localized-prostate-cancer/ Statement: The content in this article is only used to explore the frontier progress of biomedicine and does not constitute any Medical guidance, if necessary, please go to a regular hospital for treatment
.
Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
The high-end matrix users of all media reached 160,000+, of which industrial users accounted for more than 50%, and scientific research and clinical users accounted for about 30%.
More than 5% of users of investment institutions
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
September 9, 2009/eMedClub News/--Recently, Candel Therapeutics, a late-stage clinical biopharmaceutical company, announced that its new oncolytic virus immunotherapy CAN-2409 has completed a key phase 3 study in patients with high-risk local prostate cancer Recruitment of patients
.
This clinical trial aims to evaluate the therapeutic effect of CAN-2409 in combination with valacyclovir and standard-of-care radiotherapy alone in the treatment of patients with newly diagnosed localized prostate cancer with intermediate and high risk of recurrence
.
Localized prostate cancer is an androgen-dependent tumor.
Androgens can stimulate the growth of prostate cancer cells and disease progression
.
Therefore, endocrine therapy is one of the conventional treatments.
However, as the disease progresses, androgen receptor (AR) mutations, causing endocrine patients to enter a treatment-resistant state
.
However, the side effects of daily surgery and radiotherapy are obvious, and local prostate cancer patients urgently need innovative therapies that can improve their lives
.
CAN-2409 is a replication-deficient engineered virus based on adenovirus, which contains a prodrug-converting enzyme gene encoding herpes simplex virus thymidine kinase (HSV-tk)
.
HSV-tk can convert the small molecule prodrug valacyclovir (FDA approved anti-herpes drug) into toxic metabolites that kill nearby cancer cells
.
CAN-2409 is administered by intratumoral injection, and adenovirus is used as a vector to transport the kinase gene into tumor cells
.
This local intra-tumor administration method minimizes the systemic toxicity associated with systemic intravenous administration and eliminates the need for complex immune evasion or tumor-specific targeting mechanisms.
At the same time, CAN-2409 is also focused on local induction The immune response of the tumor leads to the death of immunogenic cells and the release of tumor-specific antigens in the microenvironment
.
In addition, the adenovirus vector itself sends a strong pro-inflammatory signal to the tumor microenvironment to induce an immune response mediated by specific CD8+ cytotoxic T cells against the injected tumor
.
This dual mechanism enables CAN-2409 to have a powerful and long-lasting attack on many tumor-associated antigens of patients, thereby minimizing antigen escape and tolerance
.
▲The pharmacological effects of CAN-2409 combined with valacyclovir (picture source: Candel's official website) "The combination of CAN-2409 and radiotherapy has been proven to create an immune-stimulating environment that activates the body's immune system to identify and destroy cancer cells," Dr.
Paul Peter Tak, President and CEO of Candel Therapeutics, said, “Patients with localized non-metastatic prostate cancer are in great need of new therapies to improve disease progression, while reducing long-term androgen deprivation therapy and its related side effects
.
We believe that CAN-2409 can improve the prostate.
The prognosis of cancer patients
.
” ▲ Dr.
Paul Peter Tak, President and CEO of Candel Therapeutics (picture source: Candel’s official website) For more details, scan the QR code for a complete reading.
Due to the versatility of adenovirus vectors, CAN -2409 may also have the potential to treat a variety of solid tumors
.
In several ongoing preclinical and clinical settings, CAN-2409 has shown encouraging activity as a monotherapy and in combination with standard-of-care radiotherapy, surgery, chemotherapy, and immune checkpoint inhibitor therapy
.
In addition, to date, more than 700 patients have received good safety dosing, supporting the potential for combination with other treatment strategies without excessive worrying about overlapping adverse events
.
Candel will continue to evaluate the clinical trial effects of CAN-2409 in the treatment of high-grade glioma, non-small cell lung cancer, pancreatic cancer and prostate cancer
.
Candel is a biopharmaceutical company focused on helping patients fight cancer through oncolytic virus immunotherapy.
At present, the company has established an oncolytic virus immunotherapy platform based on new genetically modified adenovirus and herpes simplex virus (HSV) constructs
.
CAN-2409 is the main product candidate for the adenovirus platform, and CAN-3110 is the main product candidate for the HSV platform
.
▲Candel Therapeutics product pipeline (picture source: Candel official website) Reference materials: 1.
https:// -can-2409-in-combination-with-valacyclovir-for-the-treatment-of-intermediate-high-risk-localized-prostate-cancer/ Statement: The content in this article is only used to explore the frontier progress of biomedicine and does not constitute any Medical guidance, if necessary, please go to a regular hospital for treatment
.
Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
The high-end matrix users of all media reached 160,000+, of which industrial users accounted for more than 50%, and scientific research and clinical users accounted for about 30%.
More than 5% of users of investment institutions
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
